ClinicalTrials.gg
CompletedNCT03471767Updated Dec 19, 2022Results posted

AXS-05 Phase II Trial on Smoking Behavior

A Phase 2 interventional study of AXS-05 and Bupropion SR in Smoking Cessation, Smoking, Cigarette and Nicotine Dependence, sponsored by James Davis. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-19.

Sponsored by James Davis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.

Enrollment
626th of 872
58 · median 149
Started
2018
with 50 others
Phase 2
105 of 920
9 open now
Registered
569th of 920
by date

Among the 920 studies in Smoking Cessation with a site in United States, this one is the 626th largest by enrollment of the 872 interventional ones that give a count, is one of 51 that started in 2018, is one of 105 in phase 2, and was the 569th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 920 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

Read the detailed description

This study aims to investigate the potential efficacy of a combination of two FDA-approved agents, sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM), for the purpose of smoking cessation treatment. DXM, a widely used over-the-counter cough suppressant, is a nicotine receptor antagonist. In fact, studies by Duke's Center for Smoking Cessation (CSC) have shown that administration of DXM leads to a decrease in self-administration of nicotine in nicotine-dependent rats. DXM, however, has not been studied in humans. DXM, when taken alone, is not expected to be useful for treating nicotine dependence in humans given DXM rapidly metabolizes in humans via CYP2D6. As a result, therapeutic concentrations needed to bind to nicotine receptors are not obtained. Therapeutic concentrations of DXM are required, therefore, to allow DXM to bind to nicotine receptors and act as a nicotine antagonist. In order to attain therapeutic concentrations of DXM a metabolism inhibitor must be introduced. BUP is a well-known FDA approved smoking cessation medication that has been shown to inhibit the metabolism of DXM. When BUP is co-administered with DXM to healthy volunteers, a significant increase in DXM plasma levels is observed.

Currently, Axsome Therapeutics Inc. (Axsome) is developing and testing an oral fixed-dose combination of IR DXM with SR BUP to achieve therapeutic concentrations of DXM. This investigational drug has been named AXS-05. Axsome has found AXS-05 to be generally safe and well-tolerated in three Phase 1 studies. The adverse event profile of AXS-05 was similar to that of BUP alone.

Given the distinct mechanisms by which BUP and DXM interact, it is hoped that combining DXM and BUP will prove more efficacious than either drug administered alone for the purpose of tobacco use treatment in humans.

03

Conditions studied

  • Smoking Cessation
  • Smoking, Cigarette
  • Nicotine Dependence

Keywords

  • Smoking cessation
  • Nicotine dependence
  • Bupropion
  • DXM
  • Nicotine addiction
  • Cigarette smoking
  • Dextromethorphan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18 years or above
  2. Daily smoker using 10 or more cigarettes per day
  3. Willing to be smoke-free for 7 days
  4. Is able to provide written (in English) to participate in the study and able to understand the procedures and study requirements.
  5. Is willing to voluntarily sign and date an informed consent form that is approved by an institutional review board before the conduct of any study procedure.

Key Exclusion Criteria:

  1. Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, bupropion)
  2. Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless tobacco)
  3. Not pregnant or breastfeeding
  4. to the use of bupropion.
  5. Additional criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    AXS-05

    Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.

    Drug: AXS-05

  • Active comparator
    Bupropion SR

    Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.

    Drug: Bupropion SR

Interventions

  • DrugAXS-05

    Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.

    Also known as: Bupropion/dextromethorphan

  • Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.

    Also known as: Wellbutrin SR, Zyban SR

06

What researchers measure

Primary outcomes

  1. Change in Smoking Intensity

    Smoking intensity refers to the number of cigarettes smoked per day.

    Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)

  2. Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels

    A biochemical marker of smoking intensity.

    Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)

Secondary outcomes

  1. Change in Smoking Behavior

    7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.

    Time frame: 3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5)

  2. Medication Adherence

    Medication adherence is measured by composite self-reported diaries.

    Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)

  3. Medication Tolerance by Self-Reported Side Effects

    Number of participants who scored 3 or higher on a 7-point Likert scale ranking severity of side effects (1-2 mild; 3-5 moderate; 6-7 severe).

    Time frame: Baseline (V1), 3-Week Follow-Up Visit (V4)

  4. Medication Tolerance by Serious Adverse Events

    Measured by FDA reporting guidelines on adverse event or serious adverse event designation.

    Time frame: Baseline (V1), 4-Week Follow-Up Visit (V5)

  5. Urinary Levels of Dextromethorphan

    Measured via Urinary Dextromethorphan testing.

    Time frame: 3-Week Follow-Up Visit (V4)

07

Results

Posted Oct 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneAXS-05Bupropion SR
Started3127
Completed2523
Not completed64
Withdrew: Withdrawal by subject31
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Pi withdrawal13

Outcome measures

PrimaryChange in Smoking Intensity

Smoking intensity refers to the number of cigarettes smoked per day.

Time frame:
Baseline (V1), 3-Week Follow-Up Visit (V4)
Reported as:
Mean · change in cigarettes per day
Change in Smoking Intensity
change in cigarettes per dayAXS-05Bupropion SR
Change in Smoking Intensity-8.49 ± 0.37-6.79 ± 0.39
Statistical analysis
  • AXS-05 vs Bupropion SR · t-test, 2 sided · p = 0.05 (This was not adjusted for multiple comparisons, because the primary hypothesis was established a-priori.) · Mean difference (final values): -1.70 · 95% CI -2.75 to -0.65
SecondaryChange in Smoking Behavior

7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.

Time frame:
3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5)
Reported as:
Count of participants · Participants
Change in Smoking Behavior
ParticipantsAXS-05Bupropion SR
Change in Smoking Behavior1612
SecondaryMedication Adherence

Medication adherence is measured by composite self-reported diaries.

Time frame:
Baseline (V1), 3-Week Follow-Up Visit (V4)
Reported as:
Mean · percentage of adherence
Medication Adherence
percentage of adherenceAXS-05Bupropion SR
Medication Adherence97.08 ± 5.9796.60 ± 5.27
SecondaryMedication Tolerance by Self-Reported Side Effects

Number of participants who scored 3 or higher on a 7-point Likert scale ranking severity of side effects (1-2 mild; 3-5 moderate; 6-7 severe).

Time frame:
Baseline (V1), 3-Week Follow-Up Visit (V4)
Reported as:
Count of participants · Participants
Medication Tolerance by Self-Reported Side Effects
ParticipantsAXS-05Bupropion SR
Medication Tolerance by Self-Reported Side Effects75
SecondaryMedication Tolerance by Serious Adverse Events

Measured by FDA reporting guidelines on adverse event or serious adverse event designation.

Time frame:
Baseline (V1), 4-Week Follow-Up Visit (V5)
Reported as:
Count of participants · Participants
Medication Tolerance by Serious Adverse Events
ParticipantsAXS-05Bupropion SR
Medication Tolerance by Serious Adverse Events00
SecondaryUrinary Levels of Dextromethorphan

Measured via Urinary Dextromethorphan testing.

Time frame:
3-Week Follow-Up Visit (V4)
Reported as:
Mean · ng/mL
Urinary Levels of Dextromethorphan
ng/mLAXS-05Bupropion SR
Urinary Levels of Dextromethorphan1902.1 ± 1304.4—
PrimaryPercentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels

A biochemical marker of smoking intensity.

Time frame:
Baseline (V1), 3-Week Follow-Up Visit (V4)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels
percentage of participantsAXS-05Bupropion SR
Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels52.030.4
Statistical analysis
  • AXS-05 vs Bupropion SR · t-test, 2 sided · p = 0.15

Adverse events

Collected over Approximately four weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/31 (0%)2/31 (6.5%)4/31 (12.9%)
Bupropion SR0/27 (0%)1/27 (3.7%)8/27 (29.6%)
Most frequent serious events
Most frequent serious events
EventAXS-05Bupropion SR
StrokeNervous system disorders0/311/27
Urinary Tract InfectionInfections and infestations1/310/27
Broken JawInjury, poisoning and procedural complications1/310/27
Most frequent other events
Most frequent other events
EventAXS-05Bupropion SR
Dry MouthGastrointestinal disorders2/313/27
HeadacheNervous system disorders0/312/27
Insomnia/Sleep DisturbancePsychiatric disorders2/312/27
Abnormal/Vivid DreamsPsychiatric disorders0/311/27

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AXS-05Bupropion SRTotal
<=18 years000
Between 18 and 65 years272653
>=65 years415
Age, Continuous
Age, Continuous(years)AXS-05Bupropion SRTotal
Mean50.03 ± 13.6146.48 ± 11.3448.38 ± 12.62
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05Bupropion SRTotal
Female161430
Male151328
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AXS-05Bupropion SRTotal
Hispanic or Latino123
Not Hispanic or Latino302555
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AXS-05Bupropion SRTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American81523
White221133
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)AXS-05Bupropion SRTotal
United States312758
08

Study locations

1 site
  • Duke Center for Smoking Cessation
    Durham, North Carolina 27705, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Mar 2019, 12 months.

Results were first posted in Oct 2022, 3 years 6 months after primary completion. A results delay was requested in Mar 2020.

Of 42 non-industry phase 2 interventional studies under Smoking Cessation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 61. This study's 12 months is below that.

Counting every sponsor, half of 51 studies reached it within 35 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Mar 21, 2018
StartActual
Mar 25, 2018
Primary completionActual
Mar 31, 2019
CompletionActual
Mar 31, 2019
Results delay requested
Mar 13, 2020
Results first posted
Oct 12, 2022
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03471767
Lead sponsor
James Davis
Responsible party
James Davis (Medical Director, Duke Center for Smoking Cessation, Duke University) — Sponsor-investigator
First posted
Mar 21, 2018
Start date
Mar 25, 2018
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019
Results posted
Oct 12, 2022
Last update
Dec 19, 2022

Study contacts

James M Davis, MD
principal investigator · Duke Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion